G-1111 GW7647, Free Acid, >99%

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 1 mg
  • 35
  • 28
  • 26
  • 3,700
  • Add to Cart Qty:
  • In stock
  • 5 mg
  • 49
  • 40
  • 36
  • 5,100
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 79
  • 65
  • 59
  • 8,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 146
  • 120
  • 109
  • 15,300
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 259
  • 214
  • 193
  • 27,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 374
  • 309
  • 280
  • 39,100
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 502.75
  • C29H46N2O3S
  • [265129-71-3]

Solubility: DMSO.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • GW7647 is a peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist.  A synergistic antinociceptive interaction between the endogenous cannabinoid receptor agonist anandamide and GW7647 was demonstrated in a model of acute chemical-induced pain.  Russo R., et al.  "Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647."  Eur. J. Pharmacol.  566(1-3): 117-119 (2007).
  • GW7647 promoted cholesterol efflux and ATP binding cassette transporter A1/G1 expression in primary macrophages.  Nakaya K., et al.  "Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway."  Arterioscler. Thromb. Vasc. Biol.  31(6): 1276-1282 (2011).
  • GW7647 increased the production of high-density lipoprotein and decreased cholesterol esterification in Caco-2/TC7 cells. Colin S., et al. "Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production." Eur. Heart J. 34(32): 2566-2574 (2013).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
1558